Scientific Publications

Search by Keyword(s)
Found 8 results

Filters: Author is Eck, MJ  [Clear All Filters]

Search Results

  • Showing 1-8 of 8 Results
2015
Structure and mechanism of activity-based inhibition of the EGF receptor by Mig6.Park, E., Kim N., Ficarro SB, Zhang Y., Lee BI, Cho A., Kim K., Park AK, Park WY, Murray B., Meyerson M., Beroukhim R., Marto JA, Cho J., and Eck MJ Nature structural & molecular biology, 2015/08/17, (2015) Read More / View Supplemental Materials
Abstract
Activity of the Type II JAK2 Inhibitor CHZ868 in B Cell Acute Lymphoblastic Leukemia.Wu, SC, Li LS, Kopp N., Montero J., Chapuy B., Yoda A., Christie AL, Liu H., Christodoulou A., van Bodegom D., van der Zwet J., Layer JV, Tivey T., Lane AA, Ryan JA, Ng SY, DeAngelo DJ, Stone RM, Steensma D., Wadleigh M., et al. Cancer cell, 2015/07/13, Volume 28, Issue 1, p.29-41, (2015) Read More / View Supplemental Materials
Abstract
2014
Inhibition of KRAS-driven tumorigenicity by interruption of an autocrine cytokine circuit.Zhu, Z., Aref AR, Cohoon TJ, Barbie TU, Imamura Y., Yang S., Moody SE, Shen RR, Schinzel AC, Thai TC, Reibel JB, Tamayo P., Godfrey JT, Qian ZR, Page AN, Maciag K., Chan EM, Silkworth W., Labowsky MT, Rozhansky L., et al. Cancer discovery, 2014/01/20, (2014) Read More / View Supplemental Materials
Abstract
2013
Cetuximab response of lung cancer-derived EGF receptor mutants is associated with asymmetric dimerization.Cho, J., Chen L., Sangji N., Okabe T., Yonesaka K., Francis JM, Flavin RJ, Johnson W., Kwon J., Yu S., Greulich HE, Johnson B. E., Eck MJ, Janne PA, Wong KK, and Meyerson M. Cancer research, 2013/09/24, (2013) Read More / View Supplemental Materials
Abstract
Structure and Ubiquitination-Dependent Activation of TANK-Binding Kinase 1.Tu, D., Zhu Z., Zhou AY, Yun CH, Lee KE, Toms AV, Li Y., Dunn GP, Chan E., Thai T., Yang S., Ficarro SB, Marto JA, Jeon H., Hahn WC, Barbie DA, and Eck MJ Cell reports, 2013/03/28, Volume 3, Issue 3, p.747-58, (2013) Read More / View Supplemental Materials
Abstract
2012
Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2.Greulich, H., Kaplan B., Mertins P., Chen TH, Tanaka KE, Yun CH, Zhang X., Lee SH, Cho J., Ambrogio L., Liao R., Imielinski M., Banerji S., Berger AH, Lawrence MS, Zhang J., Pho NH, Walker SR, Winckler W., Getz G., et al. Proceedings of the National Academy of Sciences of the United States of America, 2012/09/04, Volume 109, Issue 36, p.14476-81, (2012) Read More / View Supplemental Materials
Abstract
2005
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.Levine, RL, Wadleigh M., Cools J., Ebert BL, Wernig G., Huntly BJ, Boggon TJ, Wlodarska I., Clark JJ, Moore S., Adelsperger J., Koo S., Lee JC, Gabriel S., Mercher T., D'Andrea A., Fröhling S., Döhner K., Marynen P., Vandenberghe P., et al. Cancer cell, 2005/04/01, Volume 7, Issue 4, p.387-97, (2005) Read More / View Supplemental Materials
Abstract
2004
EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.Paez, JG, Jänne PA, Lee JC, Tracy S., Greulich H., Gabriel S., Herman P., Kaye FJ, Lindeman N., Boggon TJ, Naoki K., Sasaki H., Fujii Y., Eck MJ, Sellers WR, Johnson B. E., and Meyerson M. Science (New York, N.Y.), 2004/06/04, Volume 304, Issue 5676, p.1497-500, (2004) Read More / View Supplemental Materials
Abstract
  • Showing 1-8 of 8 Results